Anne M Schijvens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8338994/publications.pdf

Version: 2024-02-01

1477746 1199166 11 159 12 6 citations h-index g-index papers 12 12 12 269 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatric Nephrology, 2019, 34, 389-403.	0.9	50
2	Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatric Nephrology, 2017, 32, 1263-1268.	0.9	27
3	Mitochondrial Disease and the Kidney With a Special Focus on CoQ10 Deficiency. Kidney International Reports, 2020, 5, 2146-2159.	0.4	24
4	Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 201-213.	1.5	14
5	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatric Nephrology, 2019, 34, 507-515.	0.9	13
6	Pharmacokinetics in children with chronic kidney disease. Pediatric Nephrology, 2020, 35, 1153-1172.	0.9	12
7	Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis. European Journal of Pediatrics, 2021, 180, 2849-2859.	1.3	7
8	Practice variations in the management of childhood nephrotic syndrome in the Netherlands. European Journal of Pediatrics, 2021, 180, 1885-1894.	1.3	6
9	The quest for optimal control of relapses in children with nephrotic syndrome. Kidney International, 2019, 95, 717.	2.6	2
10	Need for uniform definitions in childhood nephrotic syndrome. Nephrology Dialysis Transplantation, 2021, 36, 941-945.	0.4	2
11	Low Bioavailability of Oral Tacrolimus Suspension in Pediatric Kidney Transplant Patients. Clinical Pharmacokinetics, 2020, 59, 1483-1485.	1.6	1